Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400291 | 0.86 | REN (0.53) | RENMAPK8MAPK9MAPK10NTSR1 | |
| SCHEMBL30844403 | 0.86 | REN (0.49) | RENMAPK8MAPK9MAPK10 | |
| SCHEMBL30844395 | 0.85 | REN (0.49) | RENMAPK8MAPK9MAPK10 | |
| SCHEMBL31031452 | 0.85 | KDM1A (0.52) | REN | |
| SCHEMBL31147164 | 0.85 | NTSR1 (0.49) | NTSR2NTSR1SORT1 | |
| SCHEMBL30311126 | 0.85 | REN (0.53) | RENMAPK8MAPK9MAPK10NTSR1 | |
| SCHEMBL38659833 | 0.85 | CALCRL (0.47) | RENMAPK8MAPK9MAPK10NTSR2 | |
| SCHEMBL30844293 | 0.85 | REN (0.49) | RENMAPK8MAPK9MAPK10 | |
| SCHEMBL30771413 | 0.84 | REN (0.53) | RENMAPK8MAPK9MAPK10NTSR2 | |
| SCHEMBL29801982 | 0.84 | REN (0.48) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230125233-A1 | PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4154911-A1 | PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-113880809-B | Pyrimidine derivative and preparation method and application thereof | 盛世泰科生物医药技术(苏州)有限公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125233-A1 | PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK8, WEE1, TYMP | REN 534/4885MAPK8 153/4885MAPK9 431/4885 |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | REN 3322/4885MAPK8 250/4885MAPK9 262/4885 |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | REN 4080/4885MAPK8 2844/4885MAPK9 2487/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | REN 4155/4885MAPK8 1900/4885MAPK9 2223/4885 |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK20, CDK3 | REN 632/4885MAPK8 209/4885MAPK9 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.